Endeavor’s threat to IPF incumbents increases after phase 2 win for Hedgehog inhibitor — Live Feedhttps://www.live-feeds.com/feed/endeavor-s-threat-to-ipf-incumbents-increases-after-phase-2-win-for-hedgehog-inhibitorContinuously updated, source-cited coverage. Endeavor Wins Phase 2b for IPF Drug Taladegibhttps://www.live-feeds.com/feed/endeavor-s-threat-to-ipf-incumbents-increases-after-phase-2-win-for-hedgehog-inhibitorhttps://www.live-feeds.com/feed/endeavor-s-threat-to-ipf-incumbents-increases-after-phase-2-win-for-hedgehog-inhibitor#u116444Sun, 11 Oct 2026 14:40:16 +0000Endeavor BioMedicines announced that its Phase 2b WHISTLE-PF trial of taladegib met its primary and key secondary endpoints in patients with idiopathic pulmonary fibrosis. The investigational Hedgehog signaling pathway inhibitor demonstrated a statistically significant improvement in lung function compared to placebo, measured by percent predicted forced vital capacity through Week 24. Trial results also showed reduced lung fibrosis and increased total lung capacity on quantitative high-resolution computed tomography imaging. Patients receiving the drug experienced symptomatic improvement from